Bio-Rad Laboratories, Inc. logo
Bio-Rad Laboratories, Inc. (BIO)
Compare

Bio-Rad Laboratories, Inc. (BIO) Free Cash Flow Yield: 4.54%

Is Bio-Rad Laboratories, Inc.’s free cash flow yield high or low?

Bio-Rad Laboratories, Inc.'s free cash flow yield of 4.54% is 63% above its 5-year average of 2.78%, near the high end of its 5-year range (0.54%–5.49%).

The free cash flow yield for Bio-Rad Laboratories, Inc. (BIO) is 4.54% as of Wednesday, June 10, 2026. It is above its 12-month average by 0.25% (4.53%).

BIO Free Cash Flow Yield Chart

BIO Free Cash Flow Yield
4.54%-11.84% 1Y
Zoom

BIO Average Free Cash Flow Yield Chart

BIO Current vs Average Free Cash Flow Yield Chart

BIO Free Cash Flow Yield Metrics

FREE CASH FLOW YIELD

4.54%

FREE CASH FLOW YIELD AVG TTM

4.53%

FREE CASH FLOW YIELD AVG 3Y

3.11%

FREE CASH FLOW YIELD AVG 5Y

2.78%

FREE CASH FLOW YIELD AVG 10Y

2.32%

FREE CASH FLOW YIELD AVG 15Y

2.78%

FREE CASH FLOW YIELD AVG 20Y

3.45%

CURRENT VS TTM AVG

+0.25%

CURRENT VS 3Y AVG

+45.98%

CURRENT VS 5Y AVG

+63.07%

CURRENT VS 10Y AVG

+95.33%

CURRENT VS 15Y AVG

+63.55%

CURRENT VS 20Y AVG

+31.73%

BIO Competitors' Free Cash Flow Yield

NAMEMARKET CAPFREE CASH FLOW YIELDTTM3Y5Y
Bio-Rad Laboratories, Inc. (BIO)4.54%4.53%3.11%2.78%
Charles River Laboratories International, Inc. (CRL)$9.06B4.25%6.31%5.03%4.14%
Hims & Hers Health, Inc. (HIMS)$6.42B1.15%1.43%1.61%1.61%
Align Technology, Inc. (ALGN)$12.56B5.45%5.41%3.77%3.04%
Hologic, Inc. (HOLX)$16.97B5.82%6.30%5.70%7.89%
Moderna, Inc. (MRNA)$18.40BN/A8.49%9.09%9.09%
BioNTech SE (BNTX)$21.81B6.86%3.80%18.89%19.80%
Mettler-Toledo International Inc. (MTD)$22.85B3.46%3.21%3.24%2.88%
Waters Corporation (WAT)$23.83B0.88%2.83%2.68%2.70%
Veeva Systems Inc. (VEEV)$26.73B1.91%3.52%3.07%2.74%

Yield Comparison

FCF Yield

4.54%

Earnings Yield

2.08%

Dividend Yield

N/A

Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100

How FCF Yield is used:

  • Shows free cash flow after capital expenditures relative to market cap
  • Can be compared with earnings yield and dividend yield
  • Can be compared with the company's historical range
  • Can be compared with peers that report positive free cash flow

FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.

Bio-Rad Laboratories, Inc. Free Cash Flow Yield Formula & Definition

FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Bio-Rad Laboratories, Inc. Free Cash Flow Yield FAQ

What is the free cash flow yield for Bio-Rad Laboratories, Inc. (BIO)?
The free cash flow yield for BIO stock is 4.54%.
Is Bio-Rad Laboratories, Inc.'s free cash flow yield high or low?
Bio-Rad Laboratories, Inc.'s free cash flow yield of 4.54% is 63% above its 5-year average of 2.78%, near the high end of its 5-year range (0.54%–5.49%).
What is the TTM average free cash flow yield for Bio-Rad Laboratories, Inc. (BIO)?
The TTM average free cash flow yield for BIO stock is 4.53%.
What is the 3Y average free cash flow yield for Bio-Rad Laboratories, Inc. (BIO)?
The 3Y average free cash flow yield for BIO stock is 3.11%.
What is the 5Y average free cash flow yield for Bio-Rad Laboratories, Inc. (BIO)?
The 5Y average free cash flow yield for BIO stock is 2.78%.
What is the 10Y average free cash flow yield for Bio-Rad Laboratories, Inc. (BIO)?
The 10Y average free cash flow yield for BIO stock is 2.32%.
What is the 15Y average free cash flow yield for Bio-Rad Laboratories, Inc. (BIO)?
The 15Y average free cash flow yield for BIO stock is 2.78%.
What is the 20Y average free cash flow yield for Bio-Rad Laboratories, Inc. (BIO)?
The 20Y average free cash flow yield for BIO stock is 3.45%.

Bio-Rad Laboratories, Inc. Free Cash Flow Yield History

DATEFREE CASH FLOW YIELD
2026-06-104.54%
2026-06-094.46%
2026-06-084.55%
2026-06-054.50%
2026-06-044.31%
2026-06-034.35%
2026-06-024.33%
2026-06-014.34%
2026-05-294.24%
2026-05-284.16%
2026-05-274.34%
2026-05-264.46%
2026-05-224.60%
2026-05-214.62%
2026-05-204.60%
2026-05-194.71%
2026-05-184.70%
2026-05-155.35%
2026-05-145.38%
2026-05-135.44%
2026-05-125.48%
2026-05-115.43%
2026-05-085.21%
2026-05-075.15%
2026-05-065.12%
2026-05-055.15%
2026-05-045.14%
2026-05-015.17%
2026-04-304.73%
2026-04-295.04%
2026-04-284.97%
2026-04-274.83%
2026-04-244.82%
2026-04-234.93%
2026-04-224.61%
2026-04-214.54%
2026-04-204.57%
2026-04-174.64%
2026-04-164.76%
2026-04-154.69%
2026-04-144.75%
2026-04-134.81%
2026-04-104.97%
2026-04-095.00%
2026-04-084.93%
2026-04-074.99%
2026-04-064.97%
2026-04-024.95%
2026-04-014.98%
2026-03-314.98%
2026-03-305.13%
2026-03-275.22%
2026-03-265.02%
2026-03-255.07%
2026-03-245.10%
2026-03-235.23%
2026-03-205.24%
2026-03-195.23%
2026-03-185.18%
2026-03-175.15%
2026-03-165.31%
2026-03-135.28%
2026-03-125.30%
2026-03-115.14%
2026-03-105.18%
2026-03-095.11%
2026-03-065.14%
2026-03-054.97%
2026-03-044.87%
2026-03-034.95%
2026-03-024.96%
2026-02-274.98%
2026-02-265.04%
2026-02-255.14%
2026-02-245.16%
2026-02-235.17%
2026-02-205.11%
2026-02-195.10%
2026-02-185.12%
2026-02-175.24%
2026-02-135.41%
2026-02-124.74%
2026-02-114.26%
2026-02-104.17%
2026-02-094.24%
2026-02-064.15%
2026-02-054.18%
2026-02-044.09%
2026-02-034.18%
2026-02-024.21%
2026-01-304.26%
2026-01-294.24%
2026-01-284.17%
2026-01-274.20%
2026-01-264.18%
2026-01-234.22%
2026-01-224.10%
2026-01-214.01%
2026-01-204.00%
2026-01-163.99%
2026-01-153.88%
2026-01-143.93%
2026-01-133.88%
2026-01-123.87%
2026-01-093.86%
2026-01-083.92%
2026-01-073.86%
2026-01-063.84%
2026-01-053.88%
2026-01-024.10%
2025-12-314.13%
2025-12-304.11%
2025-12-294.12%
2025-12-264.12%
2025-12-244.15%
2025-12-234.15%
2025-12-224.10%
2025-12-194.15%
2025-12-184.17%
2025-12-174.15%
2025-12-164.14%
2025-12-154.06%
2025-12-124.06%
2025-12-113.98%
2025-12-103.97%
2025-12-094.06%
2025-12-084.05%
2025-12-053.94%
2025-12-043.91%
2025-12-033.90%
2025-12-023.93%
2025-12-013.89%
2025-11-283.85%
2025-11-263.82%
2025-11-253.77%
2025-11-243.88%
2025-11-213.95%
2025-11-204.12%
2025-11-194.10%
2025-11-184.06%
2025-11-174.11%
2025-11-143.99%
2025-11-133.95%
2025-11-123.82%
2025-11-113.99%
2025-11-104.07%
2025-11-074.09%
2025-11-064.08%
2025-11-054.03%
2025-11-044.02%
2025-11-034.02%
2025-10-313.91%
2025-10-304.11%
2025-10-293.92%
2025-10-283.86%
2025-10-273.80%
2025-10-243.76%
2025-10-233.77%
2025-10-223.82%
2025-10-213.85%
2025-10-203.97%
2025-10-174.12%
2025-10-164.08%
2025-10-154.17%
2025-10-144.18%
2025-10-134.20%
2025-10-104.29%
2025-10-094.25%
2025-10-084.21%
2025-10-074.30%
2025-10-064.13%
2025-10-034.18%
2025-10-024.34%
2025-10-014.28%
2025-09-304.55%
2025-09-294.73%
2025-09-264.70%
2025-09-254.72%
2025-09-244.61%
2025-09-234.52%
2025-09-224.50%
2025-09-194.49%
2025-09-184.45%
2025-09-174.55%
2025-09-164.52%
2025-09-154.56%
2025-09-124.55%
2025-09-114.46%
2025-09-104.61%
2025-09-094.46%
2025-09-084.40%
2025-09-054.32%
2025-09-044.41%
2025-09-034.43%
2025-09-024.39%
2025-08-294.28%
2025-08-284.35%
2025-08-274.36%
2025-08-264.30%
2025-08-254.29%
2025-08-224.20%
2025-08-214.48%
2025-08-204.43%
2025-08-194.43%
2025-08-184.48%
2025-08-154.47%
2025-08-144.44%
2025-08-134.44%
2025-08-124.64%
2025-08-114.82%
2025-08-084.83%
2025-08-074.81%
2025-08-064.83%
2025-08-054.69%
2025-08-044.61%
2025-08-014.48%
2025-07-315.27%
2025-07-304.75%
2025-07-294.70%
2025-07-284.69%
2025-07-254.50%
2025-07-244.53%
2025-07-234.62%
2025-07-224.84%
2025-07-214.86%
2025-07-184.82%
2025-07-174.76%
2025-07-164.81%
2025-07-154.80%
2025-07-144.74%
2025-07-114.62%
2025-07-104.57%
2025-07-094.69%
2025-07-084.74%
2025-07-074.81%
2025-07-034.72%
2025-07-024.74%
2025-07-014.79%
2025-06-304.92%
2025-06-274.87%
2025-06-264.88%
2025-06-254.93%
2025-06-244.99%
2025-06-235.04%
2025-06-205.02%
2025-06-185.12%
2025-06-175.15%
2025-06-165.13%
2025-06-135.24%
2025-06-125.11%
2025-06-115.16%
2025-06-105.15%
2025-06-095.27%
2025-06-065.41%
2025-06-055.42%
2025-06-045.35%
2025-06-035.39%
2025-06-025.49%
2025-05-305.24%
2025-05-295.22%

Showing the most recent 260 of 4,840 data points. The chart above shows the full history.

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

Hercules, CA
7,700 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Norman D. Schwartz